In a long-anticipated ruling, the US Supreme Court acknowledged Myriad Genetics' contribution in discovering the location and sequence of the BRCA1 and BRCA2 genes, but concluded that "Myriad did not create anything" when it isolated those genes. Ass'n for Molecular Pathology v. Myriad Genetics, Inc., No. 12-398, slip op. at 12 (U.S. June 13, 2013). The Court did, however, find that laboratory-engineered complementary DNA (cDNA) remains patent-eligible under 35 U.S.C. § 101. The Court explicitly stated that it did not address the patent-eligibility of DNA sequences in which the naturally occurring nucleotides have been scientifically altered.
Click here to download PDF.
This publication is provided for your convenience and does not constitute legal advice. This publication is protected by copyright.
© 2013 White & Case LLP